Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816311 | 0.86 | NAMPT (0.34) | ITGB3ITGA2BGPR119TAAR1 | |
| SCHEMBL484279 | 0.84 | GPR119 (0.53) | GPR119 | |
| SCHEMBL485207 | 0.80 | ITGB3 (0.42) | ITGB3ITGA2BCYP2D6CHRM2CHRM3 | |
| SCHEMBL485230 | 0.80 | CYP2C19 (0.36) | ITGB3ITGA2BGPR119CYP2D6CYP2C19 | |
| SCHEMBL27166448 | 0.79 | ITGB3 (0.41) | ITGB3ITGA2BCYP2D6 | |
| SCHEMBL484653 | 0.73 | ITGB3 (0.41) | ITGB3ITGA2BCYP2D6 | |
| SCHEMBL2205934 | 0.73 | KDM4E (0.35) | — | |
| SCHEMBL8250804 | 0.73 | USP2 (0.48) | — | |
| SCHEMBL484688 | 0.72 | ITGB3 (0.40) | ITGB3ITGA2BCYP2D6 | |
| SCHEMBL22462790 | 0.72 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | ITGB3 3292/4885ITGA2B 3190/4885GPR119 206/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | ITGB3 3292/4885ITGA2B 3190/4885GPR119 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.